H. Gillenwater

发表

Phase II study of BBR 3464 as treatment in patients with sensitive or refractory small cell lung cancer

M. Socinski, N. Hanna, T. Hensing, 2006, Anti-cancer drugs.

Phase I Trial of Intrapleural Docetaxel Administered Through an Implantable Catheter in Subjects with a Malignant Pleural Effusion

S. Burks, G. Petroni, David R. Jones, 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

O-217 A randomized phase III trial of gemcitabine (G) in combination with carboplatin (C) or paclitaxel (P) versus paclitaxel plus carboplatin in advanced (Stage IIIB, IV) Non-Small Cell Lung Cancer (NSCLC)

B. P. Chandra, C. Obasaju, M. Socinski, 2003 .

Measured versus estimated glomerular filtration rate in the Calvert equation: influence on carboplatin dosing

M. Socinski, C. Lindley, J. McCune, 2001, Cancer Chemotherapy and Pharmacology.

Carfilzomib and dexamethasone vs bortezomib and dexamethasone in patients with relapsed multiple myeloma: results of the phase 3 study ENDEAVOR (NCT01568866) according to age subgroup

H. Goldschmidt, M. Dimopoulos, A. Palumbo, 2017, Leukemia & lymphoma.

Second-line chemotherapy with 96-hour infusional paclitaxel in refractory non-small cell lung cancer: report of a phase II trial.

M. Socinski, H. Gillenwater, A. Steagall, 1999, Cancer investigation.

Adjuvant chemotherapy (AC) in stage IB non-small cell lung cancer (NSCLC): Long-term follow-up of Cancer and Leukemia Group B (CALGB) 9633.

R. Schilsky, D. Sugarbaker, D. Harpole, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL

P. Riedell, T. Kipps, K. Dorritie, 2021, Blood.

Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer.

M. Socinski, G. Scagliotti, R. Govindan, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Efficacy and safety of continuous daily sunitinib dosing in previously treated advanced non-small cell lung cancer (NSCLC): Results from a phase II study

M. Socinski, R. Govindan, L. Tye, 2007 .

Serial Echocardiographic Assessment of Patients (Pts) with Relapsed Multiple Myeloma (RMM) Receiving Carfilzomib and Dexamethasone (Kd) Vs Bortezomib and Dexamethasone (Vd): A Substudy of the Phase 3 Endeavor Trial (NCT01568866)

S. Russell, H. Goldschmidt, M. Dimopoulos, 2015 .

Phase II evaluation of amifostine as an esophageal mucosal protectant in the treatment of limited-stage small cell lung cancer with chemotherapy and twice-daily radiation.

M. Socinski, R. Govindan, N. Senzer, 2002, Seminars in radiation oncology.

Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR study

H. Goldschmidt, M. Dimopoulos, A. Palumbo, 2016, Leukemia.

Transcend CLL 004: Phase 1 Cohort of Lisocabtagene Maraleucel (liso-cel) in Combination with Ibrutinib for Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

K. Dorritie, W. Wierda, T. Siddiqi, 2020 .

A phase I/II trial of weekly docetaxel and gefitinib in elderly patients with stage IIIB/IV non-small cell lung cancer.

M. Socinski, T. Stinchcombe, P. Bůžková, 2006, Lung cancer.

Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups.

David J Sugarbaker, Richard L Schilsky, R. Schilsky, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I Trial of Induction Histone Deacetylase and Proteasome Inhibition Followed by Surgery in Non–Small-Cell Lung Cancer

C. Moskaluk, S. Burks, G. Petroni, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Second-line treatment of small-cell lung cancer

H. Gillenwater, C. MacCallum, 2006, Current oncology reports.

In vivo and in vitro induction of human cytochrome P4503A4 by dexamethasone

C. Lindley, J. McCune, E. LeCluyse, 2000, Clinical pharmacology and therapeutics.

Dexamethasone Induction of Cytochrome P450 3A4 Activity in Human Hepatocytes and Healthy Volunteers

C. Lindley, E. LeCluyse, H. Gillenwater, 1999 .

A randomized, phase III multicenter trial of gemcitabine in combination with carboplatin or paclitaxel versus paclitaxel plus carboplatin in patients with advanced or metastatic non-small-cell lung cancer.

C. Obasaju, M. Socinski, M. Edelman, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

Second-line gemcitabine in refractory stage IV non small-cell lung cancer: a phase II trial.

M. Socinski, M. Schell, M. Tynan, 2000, Clinical lung cancer.

Updated Follow-up of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Treated with Lisocabtagene Maraleucel in the Phase 1 Monotherapy Cohort of Transcend CLL 004, Including High-Risk and Ibrutinib-Treated Patients

P. Riedell, T. Kipps, K. Dorritie, 2020 .